Publications by authors named "Seth Forman"

Claim this Profile
L
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.
David Rosmarin, Amit G Pandya, Thierry Passeron, Seth B Forman, Jacek Zdybski

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.
John E Harris, Kim Papp, Khaled Ezzedine, Michael Sebastian, Amit G Pandya, Seth B Forman

Br J Dermatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
Andrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, James Q Del Rosso, Zoe D Draelos, Seth B Forman

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.
Seth Forman, Dipak R Patel, Alexa B Kimball, Tarannum Jaleel, Vivian Laquer

J Am Acad Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.
Lawrence F Eichenfield, Linda F Stein Gold, Eric L Simpson, Andrea L Zaenglein, April W Armstrong, Seth B Forman

J Am Acad Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.
Vivian Y Shi, John R Ingram, Hadar Lev-Tov, Sylke Schneider-Burrus, Seth Forman

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2, Randomized, Placebo-Controlled Study of Bermekimab in Moderate-to-Severe Hidradenitis Suppurativa.
Seth Forman, Lea Kephart, Takayuki Ota, Jeff Pawlikowski, Jingzhi Jiang

J Invest Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis.
Linda Stein Gold, Robert Bissonnette, Seth Forman, Andrea Zaenglein, YuTzu Kuo

Am J Clin Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial.
Melissa Piliang, Charles Lynde, Brett King, Paradi Mirmirani, Rodney Sinclair, Seth Forman

J Am Acad Dermatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Eric L Simpson, Lawrence F Eichenfield, Kim A Papp, Seth B Forman, Adelaide A Hebert

Dermatitis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Eric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, Zoe D Draelos, Laura K Ferris, Seth B Forman

JAMA Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial.
April W Armstrong, Melinda Gooderham, Charles Lynde, Catherine Maari, Seth Forman

JAMA Dermatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation.
Andrew Alexis, James Q Del Rosso, Seth Forman, Antonio Martorell, John Browning

Int J Dermatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Seth B Forman

J Am Acad Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201.
Paul Changelian, Canxin Xu, Steve Mnich, Heidi Hope, Kourtney Kostecki, Seth Forman

JID Innov· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
Alexa B Kimball, Elena Peeva, Seth Forman, Ali Moiin, Saakshi Khattri

NEJM Evid· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial.
Lawrence F Eichenfield, Sanela Tarabar, Seth Forman, Alfonso García-Bello, Gang Feng

JAMA Dermatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Matthew J Zirwas, Zoe D Draelos, Janet DuBois, Leon H Kircik, Angela Y Moore, Seth B Forman

JAMA Dermatol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
Kim Papp, Jacek C Szepietowski, Leon Kircik, Darryl Toth, Lawrence F Eichenfield, Seth B Forman

J Am Acad Dermatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.
Melinda J Gooderham, Giampiero Girolomoni, Julian O Moore, Jonathan I Silverberg, Robert Bissonnette, Seth Forman

Dermatol Ther (Heidelb)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials.
Gil Yosipovitch, Kim Papp, Seth Forman, George Han, Jill Waibel

Br J Dermatol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
Thomas Bieber, Eric L Simpson, Jonathan I Silverberg, Diamant Thaçi, Carle Paul, Seth Forman

Immunotherapy· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease.
Jonathan T Sims, Ching-Yun Chang, Richard E Higgs, Sarah M Engle, Yushi Liu, Seth B Forman

Exp Dermatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Sophie Glatt, Gregor B E Jemec, Seth Forman, Christopher Sayed, George Schmieder

JAMA Dermatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
Brett King, Justin Ko, Seth Forman, Manabu Ohyama, Natasha Mesinkovska

J Am Acad Dermatol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis